pirenzepine has been researched along with Amentia in 23 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind parallel study allowing dose titration over 14 days, 39 agitated persons with DSM-IV dementia who were residing in long-term care facilities were administered olanzapine (N = 20) or risperidone (N = 19) as acute treatment." | 9.10 | A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. ( Fontaine, CS; Hynan, LS; Koch, K; Martin-Cook, K; Svetlik, D; Weiner, MF, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 9.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia." | 9.10 | Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002) |
| "Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine." | 5.30 | Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999) |
| " In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2." | 5.10 | Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003) |
| "In a double-blind parallel study allowing dose titration over 14 days, 39 agitated persons with DSM-IV dementia who were residing in long-term care facilities were administered olanzapine (N = 20) or risperidone (N = 19) as acute treatment." | 5.10 | A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. ( Fontaine, CS; Hynan, LS; Koch, K; Martin-Cook, K; Svetlik, D; Weiner, MF, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 5.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia." | 5.10 | Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. ( Beasley, CM; Beckett, LM; Breier, A; David, SR; Feldman, PD; Jones, B; Meehan, KM; Mintzer, JE; Nisivoccia, JR; Wang, H, 2002) |
| " This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| "Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine." | 1.30 | Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kołaczkowski, M | 3 |
| Marcinkowska, M | 3 |
| Bucki, A | 3 |
| Pawłowski, M | 3 |
| Mitka, K | 1 |
| Jaśkowska, J | 1 |
| Kowalski, P | 1 |
| Kazek, G | 2 |
| Siwek, A | 3 |
| Wasik, A | 2 |
| Wesołowska, A | 3 |
| Mierzejewski, P | 3 |
| Bienkowski, P | 2 |
| Śniecikowska, J | 2 |
| Jastrzębska-Więsek, M | 2 |
| Partyka, A | 2 |
| Więckowski, K | 1 |
| Głuch-Lutwin, M | 1 |
| Gryboś, A | 1 |
| Pytka, K | 1 |
| Ishioh, M | 1 |
| Nozu, T | 1 |
| Miyagishi, S | 1 |
| Igarashi, S | 1 |
| Funayama, T | 1 |
| Ohhira, M | 1 |
| Okumura, T | 1 |
| Bullock, R | 1 |
| Saharan, A | 1 |
| Suh, H | 1 |
| Bronson, B | 1 |
| Martin, R | 1 |
| Motsinger, CD | 1 |
| Perron, GA | 1 |
| Lacy, TJ | 1 |
| Battaglia, J | 1 |
| Lindborg, SR | 1 |
| Alaka, K | 1 |
| Meehan, K | 1 |
| Wright, P | 1 |
| Fontaine, CS | 1 |
| Hynan, LS | 1 |
| Koch, K | 1 |
| Martin-Cook, K | 1 |
| Svetlik, D | 1 |
| Weiner, MF | 1 |
| Reeves, RR | 1 |
| Torres, RA | 1 |
| Teaktong, T | 1 |
| Piggott, MA | 1 |
| Mckeith, IG | 2 |
| Perry, RH | 1 |
| Ballard, CG | 1 |
| Perry, EK | 1 |
| Tsang, SW | 1 |
| Lai, MK | 1 |
| Kirvell, S | 1 |
| Francis, PT | 1 |
| Esiri, MM | 1 |
| Hope, T | 1 |
| Chen, CP | 1 |
| Wong, PT | 1 |
| Caulfield, MP | 1 |
| Straughan, DW | 1 |
| Cross, AJ | 1 |
| Crow, T | 1 |
| Birdsall, NJ | 1 |
| Maeda, T | 1 |
| Satoh, M | 1 |
| Glazer, WM | 1 |
| Finkel, SI | 1 |
| Jeste, DV | 1 |
| Rockwell, E | 1 |
| Harris, MJ | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Walker, Z | 1 |
| Grace, J | 1 |
| Overshot, R | 1 |
| Satarasinghe, S | 1 |
| Swan, A | 1 |
| Katona, CL | 1 |
| Aarsland, D | 1 |
| Larsen, JP | 1 |
| Lim, NG | 1 |
| Tandberg, E | 1 |
| Buckley, PF | 1 |
| Ellingrod, VL | 1 |
| Schultz, SK | 1 |
| Ekstam-Smith, K | 1 |
| Kutscher, E | 1 |
| Turvey, C | 1 |
| Arndt, S | 1 |
| Meehan, KM | 1 |
| Wang, H | 1 |
| David, SR | 1 |
| Nisivoccia, JR | 1 |
| Jones, B | 1 |
| Beasley, CM | 1 |
| Feldman, PD | 1 |
| Mintzer, JE | 1 |
| Beckett, LM | 1 |
| Breier, A | 1 |
6 reviews available for pirenzepine and Amentia
| Article | Year |
|---|---|
Atypical antipsychotics: experience and use in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; | 2002 |
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
Managing the behavioral and psychological signs and symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dementia; Humans; | 1997 |
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
4 trials available for pirenzepine and Amentia
| Article | Year |
|---|---|
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl | 2003 |
A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Blind Method; Drug Administration Sche | 2003 |
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Female; Humans; | 2002 |
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.
Topics: Acute Disease; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Bl | 2002 |
13 other studies available for pirenzepine and Amentia
| Article | Year |
|---|---|
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; C | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indol | 2015 |
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
Topics: Affect; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Dementia; Dopamine Agonist | 2017 |
Activation of basal forebrain cholinergic neurons improves colonic hyperpermeability through the vagus nerve and adenosine A2B receptors in rats.
Topics: Adenosine; Animals; Basal Forebrain; Butyrates; Cholinergic Agents; Cholinergic Neurons; Dementia; O | 2022 |
Neuroleptic malignant syndrome and low-dose olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship | 2003 |
Use of atypical antipsychotic drugs in patients with dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Dementia; Dibenzothiazepines; H | 2003 |
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepi | 2003 |
Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Autoradiography; Binding, Competitive; Case-Control S | 2005 |
Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brain Chemistry; Choline O-Acetylt | 2006 |
Cortical muscarinic receptor subtypes and Alzheimer's disease.
Topics: Alzheimer Disease; Benzodiazepinones; Binding, Competitive; Cerebral Cortex; Dementia; Humans; N-Met | 1982 |
[Experimental techniques for developing new drugs acting on dementia (3)--Experimental methods on the long-term potentiation].
Topics: Animals; Cholinergic Agents; Dementia; Guinea Pigs; Hippocampus; In Vitro Techniques; Long-Term Pote | 1994 |
Olanzapine in dementia with Lewy bodies: a clinical study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Contraindicatio | 1999 |
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship, Drug; Female; Hum | 1999 |